Beigene Ltd ADR (NQ: BGNE )
206.72
-2.59
(-1.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 25, 2024
Add to My Watchlist
All News about Beigene Ltd ADR
FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic Leukemia
January 20, 2023
Via Benzinga
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
January 19, 2023
From BeiGene
Via Business Wire
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
January 18, 2023
From BeiGene
Via Business Wire
Via Benzinga
Via Talk Markets
From BeiGene
Via Business Wire
BeiGene Earnings Perspective: Return On Capital Employed
December 12, 2022
Via Benzinga
What 5 Analyst Ratings Have To Say About BeiGene
December 12, 2022
Via Benzinga
Will Investors Notice Exciting Sign On BeiGene's Chart?
December 06, 2022
Via Benzinga
Via Benzinga
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
November 10, 2022
From BeiGene
Via Business Wire
BeiGene Reports Third Quarter 2022 Financial Results
November 09, 2022
From BeiGene, Ltd.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.